Developer docs
API playgroundTry for free, no card

Search company profiles

PixarBio

Full company profile

uuid00068s5

Namestring
PixarBio
Websiteurl
pixarbio.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

PixarBio Corp is a publicly traded specialty biotechnology company headquartered in Medford, United States. Founded in 2013 and trading on the OTCQX market under the ticker PXRB, the company is described in its own firmographic profile as focused on the pre-clinical and commercial development of new products. Per available firmographic data, the firm operates as a for-profit entity with 11-50 employees.

Leadership is concentrated in a three-founder structure. Frank Reynolds is listed as Chairman of the Board and concurrently holds the CEO, CFO, and CSO titles. Jason Criscione is CTO and co-founder, and Katrin Holzhaus is co-founder and COO. The consolidation of executive functions in a single founder is consistent with a small, founder-led development-stage biotech rather than a scaled commercial organization, and signals limited operational headcount beyond the founding team.

The available input discloses two financing rounds dated November 18, 2016 totaling $17 million ($10 million and $7 million) as the only dated capital-markets activity. No revenue, products or services, partnerships, customers, patent portfolio, awards, regulatory actions, M&A, or recent product launches are present in the source material. Separately, a large structured data block labeled under PixarBio describes CGI animation technology, theatrical releases, merchandise partnerships, and Disney distribution — these statements pertain to Pixar Animation Studios, a wholly separate Disney-owned entity, and are not characteristics of PixarBio Corp.

Short descriptiontext

PixarBio Corp is a publicly traded specialty biotechnology company focused on pre-clinical and commercial development of new products, headquartered in Medford, United States. Founded in 2013, the firm trades on the OTCQX market under PXRB.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersFort Myers, United States
HQ citystring
Fort Myers
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
specialty biotechnology, preclinical development, therapeutic products, biopharmaceutical development, commercial drug development
Industry2 codes
PRIMARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Specialty Biotechnology
Social media profiles2 records
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Personnel, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

PixarBio Corp is a specialty biotechnology company focused on pre-clinical and commercial development of new products. The company engages in research and development activities to advance therapeutic candidates through pre-clinical stages and toward commercialization within the specialty biotechnology sector.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Toy Story 5 set for theatrical release June 19, 2026
+4 more records
Partnership8 partners
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2026-05-19
Description

Funko unveiled Toy Story 5 Funko Pop figurines featuring updated versions of Woody, Buzz Lightyear, Jessie, and new character Lilypad. Standard vinyl figures priced at $14.88 each, plus blind box-style Funko Mystery Mini Packs with 12 characters.

Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2026-05-18
Description

Fresh Del Monte launched a global marketing campaign in partnership with Disney and Pixar's Toy Story 5, featuring co-branded packaging on bananas and pineapples across more than 90 countries. The campaign includes in-store activations, digital promotions, and sweepstakes offering grocery shoppers a five-night trip to Barcelona.

Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2026-05-15
Description

Dr. Squatch and Jukebox launched a limited-edition grooming collection in collaboration with Disney and Pixar inspired by Toy Story 5, featuring bar soaps and deodorants. Collection priced from $8 for individual bars to $48.45 for a 5-pack, available ahead of film's June 19, 2026 release.

Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2026-05-07
Description

Sharpie and Elmer's, brands under Newell Brands, launched a limited-edition collection of markers, glue sticks, and slime kits inspired by Toy Story 5, featuring Woody, Buzz Lightyear, and Jessie on product packaging. Products available at Amazon, Walmart, and Target, priced from $3.47 to $29.99 MSRP.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-20
Description

Disney and Pixar released Toy Story 5 on June 19 accompanied by an extensive toy line developed in partnership with Mattel. The new toy line features advanced technology including animatronics and interactive features, representing the biggest technological leap for Mattel in their toy designs.

6ESPN/NFL
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-12-08
Description

NFL, Disney, Pixar, ESPN, Sony, and Hawk-Eye Innovations collaborated to present Monsters Funday Football, a real-time animated NFL game featuring Philadelphia Eagles and Los Angeles Chargers in the world of Monsters, Inc.

espnpressroom.com
Strategic tierMinorTypeGTM or Marketing Partner
Description

Disney leveraged unexpected viral momentum for Hoppers through Fortnite crossover content with Epic Games, along with influencer events and Super Bowl broadcasts.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Dr. Squatch partnered with Fandango to offer a $5 promo code toward movie tickets for qualifying purchases of Toy Story 5-inspired products.

Recent move2 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight1 record

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Large CRO with deep pre-clinical and discovery services offerings; comparable as a broader incumbent operating in the pre-clinical development space that PixarBio's pipeline implicitly depends on.

TypeEmerging player
Description

Emerging CDMO/biologics development services provider serving pre-clinical biotech clients; comparable as a small specialized biotech-services peer in the broader pre-clinical ecosystem.

TypeDirect peer
Description

Small-cap public specialty pharmaceutical company; comparable to PixarBio as a publicly traded specialty pharma with limited headcount and a development-stage product portfolio.

TypeBroad incumbent
Description

Established contract research/pre-clinical services platform supporting drug development; broadly comparable to PixarBio's pre-clinical development orientation, though larger and services-model rather than asset-owning.

TypeBroad incumbent
Description

Public specialty pharma with a portfolio of royalty/milestone-driven assets; comparable as a publicly traded specialty pharmaceutical business model, though significantly larger and more diversified than PixarBio.

TypeBroad incumbent
Description

Public specialty life-sciences tools and services provider; comparable as a public specialty life-sciences company with a similar small-mid cap profile but broader commercial reach.

TypeDirect peer
Description

Small-cap U.S. specialty oncology/pre-clinical biotech listed on Nasdaq, comparable to PixarBio as a publicly traded developer of a focused pipeline asset with limited headcount.

TypeDirect peer
Description

Public specialty biotech / enzyme engineering company; comparable as a small public specialty biotech pursuing platform-based product development rather than single-asset generic play.

TypeDirect peer
Description

Small public biotech focused on specialty pre-clinical and early-commercial development; directly comparable to PixarBio in stage, scale, and specialty biotech orientation.

TypeDirect peer
Description

Small-cap U.S. public specialty pharmaceutical company developing pre-clinical and clinical-stage specialty therapeutics; directly comparable to PixarBio as a publicly listed specialty pharma of similar scale.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat1 record

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

PixarBio

Specialty Biotechnologypixarbio.com

PixarBio Corp is a publicly traded specialty biotechnology company focused on pre-clinical and commercial development of new products, headquartered in Medford, United States. Founded in 2013, the firm trades on the OTCQX market under PXRB.

What PixarBio does

PixarBio Corp is a publicly traded specialty biotechnology company headquartered in Medford, United States. Founded in 2013 and trading on the OTCQX market under the ticker PXRB, the company is described in its own firmographic profile as focused on the pre-clinical and commercial development of new products. Per available firmographic data, the firm operates as a for-profit entity with 11-50 employees.

Leadership is concentrated in a three-founder structure. Frank Reynolds is listed as Chairman of the Board and concurrently holds the CEO, CFO, and CSO titles. Jason Criscione is CTO and co-founder, and Katrin Holzhaus is co-founder and COO. The consolidation of executive functions in a single founder is consistent with a small, founder-led development-stage biotech rather than a scaled commercial organization, and signals limited operational headcount beyond the founding team.

The available input discloses two financing rounds dated November 18, 2016 totaling $17 million ($10 million and $7 million) as the only dated capital-markets activity. No revenue, products or services, partnerships, customers, patent portfolio, awards, regulatory actions, M&A, or recent product launches are present in the source material. Separately, a large structured data block labeled under PixarBio describes CGI animation technology, theatrical releases, merchandise partnerships, and Disney distribution — these statements pertain to Pixar Animation Studios, a wholly separate Disney-owned entity, and are not characteristics of PixarBio Corp.

PixarBio firmographics

Firmographics
Name
PixarBio
Website
https://pixarbio.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
PixarBio Corp is a publicly traded specialty biotechnology company focused on pre-clinical and commercial development of new products, headquartered in Medford, United States. Founded in 2013, the firm trades on the OTCQX market under PXRB.
Ownership category
akta.pro rank

PixarBio industry classification

Industry
Product category
Specialty Biotechnology
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

Keywords

  • Specialty biotechnology
  • Preclinical development
  • Therapeutic products
  • Biopharmaceutical development
  • Commercial drug development

Where PixarBio is headquartered

Location

Headquarters

HQ city
Fort Myers
HQ country
United States
HQ region
North America

Markets served

PixarBio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations

Distribution channels3 records

Marketing channels4 records

PixarBio product offering

Product offering

Core offering

PixarBio Corp is a specialty biotechnology company focused on pre-clinical and commercial development of new products. The company engages in research and development activities to advance therapeutic candidates through pre-clinical stages and toward commercialization within the specialty biotechnology sector.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

  • Toy Story 5 set for theatrical release June 19, 2026
  • +4 more outcomes

Companies that use PixarBio

Customer profile

Segments1 record

Ideal customer profiles1 record

PixarBio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

PixarBio partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered minor and core.

  • FunkominorGTM or Marketing Partner · 19 May 2026Funko unveiled Toy Story 5 Funko Pop figurines featuring updated versions of Woody, Buzz Lightyear, Jessie, and new character Lilypad. Standard vinyl figures priced at $14.88 each, plus blind box-style Funko Mystery Mini Packs with 12 characters.
  • Fresh Del MonteminorGTM or Marketing Partner · 18 May 2026Fresh Del Monte launched a global marketing campaign in partnership with Disney and Pixar's Toy Story 5, featuring co-branded packaging on bananas and pineapples across more than 90 countries. The campaign includes in-store activations, digital promotions, and sweepstakes offering grocery shoppers a five-night trip to Barcelona.
  • Dr. Squatch and JukeboxminorGTM or Marketing Partner · 15 May 2026Dr. Squatch and Jukebox launched a limited-edition grooming collection in collaboration with Disney and Pixar inspired by Toy Story 5, featuring bar soaps and deodorants. Collection priced from $8 for individual bars to $48.45 for a 5-pack, available ahead of film's June 19, 2026 release.
  • Newell Brands (Sharpie and Elmer's)minorGTM or Marketing Partner · 7 May 2026Sharpie and Elmer's, brands under Newell Brands, launched a limited-edition collection of markers, glue sticks, and slime kits inspired by Toy Story 5, featuring Woody, Buzz Lightyear, and Jessie on product packaging. Products available at Amazon, Walmart, and Target, priced from $3.47 to $29.99 MSRP.
  • MattelcoreStrategic or Co-development Partner · 20 April 2026Disney and Pixar released Toy Story 5 on June 19 accompanied by an extensive toy line developed in partnership with Mattel. The new toy line features advanced technology including animatronics and interactive features, representing the biggest technological leap for Mattel in their toy designs.
  • ESPN/NFLminorStrategic or Co-development Partner · 8 December 2025NFL, Disney, Pixar, ESPN, Sony, and Hawk-Eye Innovations collaborated to present Monsters Funday Football, a real-time animated NFL game featuring Philadelphia Eagles and Los Angeles Chargers in the world of Monsters, Inc.
  • Epic Games (Fortnite)minorGTM or Marketing PartnerDisney leveraged unexpected viral momentum for Hoppers through Fortnite crossover content with Epic Games, along with influencer events and Super Bowl broadcasts.
  • FandangominorGTM or Marketing PartnerDr. Squatch partnered with Fandango to offer a $5 promo code toward movie tickets for qualifying purchases of Toy Story 5-inspired products.

Recent moves2 records

Expansion highlights1 record

PixarBio competitors and assessment

Company assessment

Broad incumbents

  • Charles River Laboratories: Large CRO with deep pre-clinical and discovery services offerings; comparable as a broader incumbent operating in the pre-clinical development space that PixarBio's pipeline implicitly depends on.
  • Inotiv: Established contract research/pre-clinical services platform supporting drug development; broadly comparable to PixarBio's pre-clinical development orientation, though larger and services-model rather than asset-owning.
  • Ligand Pharmaceuticals: Public specialty pharma with a portfolio of royalty/milestone-driven assets; comparable as a publicly traded specialty pharmaceutical business model, though significantly larger and more diversified than PixarBio.
  • Maravai LifeSciences: Public specialty life-sciences tools and services provider; comparable as a public specialty life-sciences company with a similar small-mid cap profile but broader commercial reach.

Emerging players

  • Bionova Scientific: Emerging CDMO/biologics development services provider serving pre-clinical biotech clients; comparable as a small specialized biotech-services peer in the broader pre-clinical ecosystem.

Direct peers

  • Aytu BioPharma: Small-cap public specialty pharmaceutical company; comparable to PixarBio as a publicly traded specialty pharma with limited headcount and a development-stage product portfolio.
  • Aprea Therapeutics: Small-cap U.S. specialty oncology/pre-clinical biotech listed on Nasdaq, comparable to PixarBio as a publicly traded developer of a focused pipeline asset with limited headcount.
  • Codexis: Public specialty biotech / enzyme engineering company; comparable as a small public specialty biotech pursuing platform-based product development rather than single-asset generic play.
  • BioRestorative Therapies: Small public biotech focused on specialty pre-clinical and early-commercial development; directly comparable to PixarBio in stage, scale, and specialty biotech orientation.
  • Tonix Pharmaceuticals: Small-cap U.S. public specialty pharmaceutical company developing pre-clinical and clinical-stage specialty therapeutics; directly comparable to PixarBio as a publicly listed specialty pharma of similar scale.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat1 record

Key risks5 records

Key highlights5 records

Customer concentration

PixarBio social profiles

Digital presence

PixarBio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

PixarBio leadership team

Management profile

Number of profiles

Profiles3 records

PixarBio funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

PixarBio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PixarBio

What does PixarBio do?

PixarBio Corp is a specialty biotechnology company focused on pre-clinical and commercial development of new products. The company engages in research and development activities to advance therapeutic candidates through pre-clinical stages and toward commercialization within the specialty biotechnology sector.

Is PixarBio a public or private company?

PixarBio is a private company. It is classified as public and is currently operating.

When was PixarBio founded?

PixarBio was founded in 2013. It employs 11 to 50 people.

Where is PixarBio based?

PixarBio is headquartered in Fort Myers, United States, in the North America region.

Who are PixarBio's main competitors?

Broad incumbents on record are Charles River Laboratories, Inotiv, Ligand Pharmaceuticals and Maravai LifeSciences. Bionova Scientific is listed as an emerging player. Direct peers are Aytu BioPharma, Aprea Therapeutics, Codexis, BioRestorative Therapies and Tonix Pharmaceuticals.

Does PixarBio have an API?

No public API is recorded for PixarBio.

What industry is PixarBio in?

PixarBio's product category is Specialty Biotechnology. Its primary akta.pro industry code is HLAIAAAA, Primary Care & General Medicine Pharmaceuticals, with a secondary code of HLAGAHAL, GMP Scale-Up, Tech Transfer & Process Validation (PPQ). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireSHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In PixarBio Corporation To Contact The Firm Before Imminent Lead Plaintiff DeadlineA federal securities class action lawsuit was filed against PixarBio Corporation in the U.S. District Court for the District of New Jersey on behalf of investors who purchased securities during the private placement that closed October 30, 2016, or on the open market between October 31, 2016 and January 20, 2017. On January 23, 2017, the SEC announced a temporary suspension of trading in PixarBio securities, citing concerns about manipulative or deceptive activities and accuracy issues with the company's press releases and Form S-1. The deadline for investors to seek the role of lead plaintiff in the class action is March 27, 2017.PR NewswireEQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against PixarBio Corporation - PXRBRosen Law Firm filed a securities class action lawsuit against PixarBio Corporation (PXRB) on behalf of investors who purchased securities during two specified periods in late 2016 and early 2017. The lawsuit alleges that defendants made false and misleading statements about manipulative market activities and misrepresented key facts regarding business combinations, shareholder identities, and development efforts. Investors who suffered damages are being invited to join the class action, with a motion deadline for lead plaintiff set for March 27, 2017.PR NewswirePXRB INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving PixarBio Corporation and a Lead Plaintiff Deadline of March 27, 2017The Law Offices of Vincent Wong filed a class action lawsuit in the US District Court for the District of New Jersey against PixarBio Corporation alleging securities fraud. The suit covers investors who purchased PixarBio securities through a private placement closing on October 30, 2016, or on the open market from October 31, 2016 through January 20, 2017. The complaint alleges that PixarBio made false and misleading statements and failed to disclose manipulative or deceptive market activities, with a lead plaintiff deadline of March 27, 2017.PR NewswireBlock & Leviton Reminds PixarBio Corporation Investors Of Important Deadline In Securities Fraud Class ActionBlock & Leviton LLP is reminding investors of a March 27, 2017 deadline to serve as lead plaintiff in a securities fraud class action against PixarBio Corporation. The lawsuit follows the SEC's halt of PixarBio's trading and a subsequent 35% stock plunge due to alleged manipulative activities and misleading statements regarding business combinations and corporate governance.PR NewswireJohnson & Weaver, LLP Announces Investigations of Clovis Oncology, Inc., USANA Health Sciences, Inc., Anthera Pharmaceuticals, Inc., and PixarBio CorporationShareholder rights law firm Johnson & Weaver, LLP announced investigations into potential federal and state securities law violations at four companies: Clovis Oncology, USANA Health Sciences, Anthera Pharmaceuticals, and PixarBio Corporation. For Anthera specifically, the lawsuit alleges the company made misleading statements about clinical trials that subsequently failed, causing shares to drop approximately 63% on December 28, 2016. For PixarBio, the SEC temporarily suspended trading on January 23, 2017 citing apparent manipulative or deceptive activities and inaccurate public statements.PR NewswirePIXARBIO SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against PKahn Swick & Foti, LLC, a securities law firm, has reminded investors of a March 27, 2017 deadline to file lead plaintiff applications in a class action lawsuit against PixarBio Corporation for alleged federal securities law violations. The lawsuit, pending in the U.S. District Court for the District of New Jersey, claims that PixarBio and certain executives failed to disclose material information during the class period from October 30, 2016 to January 20, 2017, including manipulative or deceptive market activities and false statements about business combinations and key personnel.PR NewswireLifshitz & Miller LLP Announces Investigation of Dr. Reddy's Laboratories Limited, Exterran Corporation, Gigamon Inc., KemPharm, Inc., Navient Corporation, NCI, Inc., Opus Bank, PixarBio Corporation aLifshitz & Miller LLP announced ongoing securities class action investigations on behalf of investors for nine publicly traded companies: Dr. Reddy's Laboratories, Exterran Corporation, Gigamon Inc., KemPharm Inc., Navient Corporation, NCI Inc., Opus Bank, PixarBio Corporation, and Yahoo! Inc. The investigations address various corporate issues including FDA warning letters, accounting irregularities, product booking reductions, labeling controversies, loan servicing practices, embezzlement, loan quality representations, business combination assertions, and massive data breaches.PR NewswirePixarBio Corporation Sued By Block & Leviton For Violations Of The Federal Securities LawsBlock & Leviton LLP filed a class action lawsuit against PixarBio Corporation and its CEO Frank Reynolds on January 30, 2017, alleging violations of federal securities laws for failing to disclose and making false/misleading statements about business combinations, key personnel, and development efforts. The lawsuit follows a disputed $100 million takeover bid for InVivo Therapeutics that InVivo rejected as "not credible," and the SEC's January 23 halt of trading in PixarBio securities citing concerns about possible manipulative or deceptive activities. PixarBio stock fell nearly 37% since January 3, causing tens of millions in losses to investors during the class period of October 31, 2016 through January 20, 2017.PR NewswireJohnson & Weaver, LLP Announces Investigations of The Southern Company, Illumina, Inc., PixarBio Corporation and Midcoast Energy Partners, L.P.Johnson & Weaver filed class action lawsuits against The Southern Company, Illumina, PixarBio, and Midcoast Energy Partners. The suits allege false statements and failures to disclose, including overstatements of demand and inadequate consideration in a proposed acquisition. Lead plaintiff deadlines are set for February 14 and March 27, 2017.PR NewswireJohnson & Weaver, LLP Announces Investigations of The Southern Company, Illumina, Inc., PixarBio Corporation and Midcoast Energy Partners, L.P.Shareholder rights law firm Johnson & Weaver, LLP announced the filing of three securities class action lawsuits against Southern Company, Illumina, Inc., and PixarBio Corporation, alleging materially false and misleading statements during specified class periods that caused investor damages. The lawsuits claim Southern Company concealed Kemper Plant cost overruns and delays, Illumina overstated demand for its sequencing instruments while hiding revenue-impacting sales declines, and PixarBio engaged in manipulative trading with inaccurate disclosures about business combinations and shareholders. The SEC has temporarily suspended trading in PixarBio securities, and the firm separately launched an investigation into Midcoast Energy Partners' board regarding its handling of a proposed acquisition by Enbridge Energy at $8.00 per unit.